

GenCore version 5.1.4\_p5\_4578  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: April 16, 2003, 12:10:40 ; Search time 36 Seconds

(without alignments)  
440.467 Million cell updates/sec

Title: US-10-015-967-2

Perfect score: 644  
Sequence: 1 MVLISLLLLPLMLSMV.....SRACQFLKQCLRSFALPL 119

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 08  
Maximum Match 100%

Listing first 45 summaries

Database :

A\_Geneseq\_101002:\*

1: /SID52/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:\*  
2: /SID52/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:\*  
3: /SID52/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:\*  
4: /SID52/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:\*  
5: /SID52/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:\*  
6: /SID52/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:\*  
7: /SID52/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:\*  
8: /SID52/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:\*  
9: /SID52/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:\*  
10: /SID52/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:\*  
11: /SID52/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:\*  
12: /SID52/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:\*  
13: /SID52/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:\*  
14: /SID52/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:\*  
15: /SID52/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:\*  
16: /SID52/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:\*  
17: /SID52/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:\*  
18: /SID52/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:\*  
19: /SID52/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:\*  
20: /SID52/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:\*  
21: /SID52/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:\*  
22: /SID52/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:\*  
23: /SID52/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	644	100.0	119	21	Human secreted pro
2	644	100.0	119	21	Human TGC-440 secr
3	644	100.0	119	21	Human signal pepti
4	644	100.0	119	21	Membrane-bound pro
5	644	100.0	119	22	Human PRO polypept
6	644	100.0	119	22	Amino acid sequenc
7	644	100.0	119	22	Human PRO842. Hom
8	644	100.0	119	22	Human PRO842 (UN04
9	548	85.1	97	21	Mature human TGC-4
10	527	81.8	93	19	Polypeptide encode

11	456	70.8	119	21	AA182457
12	386	59.9	97	21	AA182458
13	386	59.9	119	21	AA182459
14	358	55.6	69	20	AA11732
15	342	53.1	97	21	AA182456
16	296	46.0	64	19	AA183928
17	225	34.9	48	20	AA111731
18	78.5	12.2	191	22	AA066308
19	73.5	11.4	70	14	AA191996
20	73.5	11.4	70	14	AA191996
21	71.5	11.1	108	23	AA021337
22	71	11.0	330	22	ABG25331
23	71	11.0	1798	19	AA150896
24	71	11.0	3190	22	AA184634
25	71	11.0	3275	22	AB170437
26	70.5	10.9	146	23	AA183095
27	70	10.9	117	23	AB161841
28	70	10.9	121	20	AA166185
29	70	10.9	121	21	AA166185
30	70	10.9	167	20	AA166185
31	70	10.9	167	21	AA166185
32	70	10.9	167	21	AA166185
33	70	10.9	167	21	AA166185
34	70	10.9	167	21	AA166185
35	70	10.9	167	21	AA166185
36	70	10.9	167	21	AA166185
37	70	10.9	167	21	AA166185
38	70	10.9	167	21	AA166185
39	70	10.9	167	21	AA166185
40	70	10.9	167	21	AA166185
41	70	10.9	167	21	AA166185
42	70	10.9	167	21	AA166185
43	70	10.9	167	21	AA166185
44	70	10.9	167	21	AA166185
45	70	10.9	167	21	AA166185

## ALIGNMENTS

RESULT 1	AA182457
ID	AA182457 standard; Protein, 119 AA.
XX	AA182457:
XX	26-JAN-2001 (first entry)
DE	Human secreted protein encoded by DNA clone vq8 1.
KW	Secreted protein; human; autoimmune disorder; multiple sclerosis; ulcer;
KW	systemic lupus erythematosus; rheumatoid arthritis; anaemia; stroke;
KW	haematopoiesis regulation; tissue regrowth; wound healing; haemophilia;
KW	Alzheimer's disease; Parkinson's disease; Shy-draeger syndrome; cancer;
KW	contractile; infection; growth inhibition; hyperproliferative disorder;
OS	porcine.
XX	Homo sapiens.
XX	WO20005375-A1.
XX	21-SEP-2000.
XX	17-MAR-2000; 2000MO-US07285.
XX	17-MAR-1999; 99US-0124808.
XX	17-MAR-1999; 99US-0124916.
XX	17-AUG-1999; 99US-0149639.
XX	01-OCT-1999; 99US-0157247.
XX	29-NOV-1999; 99US-0167824.
XX	15-FEB-2000; 2000US-0182711.
XX	(ALPH-) ALPHAGEN INC.

Mouse TGC-440 secr  
Mature mouse TGC-4  
Rat TGC-440 secret  
Human 5' EST secre  
Mature rat TGC-440  
Human secreted pro  
Human 5' EST secre  
Proionibacterium  
Part of chick vita  
Chicken vitamin D  
Arabidopsis thaila  
Novel human diagno  
Human laminin B2 c  
Amino acid sequenc  
Drosophila melanog  
Novel secreted pro  
Prostate cancer-as  
Human bladder tumo  
Human prostate can  
Human growth facto  
Human PRO834 matur  
Fibrosarcoma vascu  
Vascular endothell  
Parapox virus VEGF  
Human vascular end  
Human VEGF protein  
Human PRO834 prove  
Polypeptide for hu  
Human VEGF-167 pr  
Human vascular end  
Hexa-His-tagged hu  
Human ovarian anti  
Physcomitrella pat  
Drosophila melanog

XX Valenzuela D, Yuan O, Hoffman H, Hall J, Rapiejko P,  
 PI WPI; 2000-638211/61.  
 XX N-PSDB; AAC59829.  
 DR  
 XX  
 PT Novel proteins and polypeptides useful for the treatment of e.g.  
 PT multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis,  
 PT cancer, Alzheimer's disease, Parkinson's disease, stroke, anemia and  
 PT ulcers  
 PS  
 XX  
 PS Claim 92; Page 441-442; 493pp; English.  
 CC This invention relates to 59 human secreted proteins and the nucleotide  
 CC sequences encoding them. Sequences AAC59788-C59846 and AAB34687-834745  
 CC represent the proteins and their encoding nucleotide sequences, and  
 CC sequences AAB34746-834771 represent fragments of the proteins. Probes  
 CC for the DNA sequences are represented by sequences AAC59847-C59596. The  
 CC proteins exhibit neuroprotective, dermatological, immunosuppressive,  
 CC antiinflammatory, antianemic, nootropic, antiparkinsonian,  
 CC cerebroprotective, haemostatic, vulnery, cytostatic, antipsoriatic,  
 CC antibacterial, virucide, and fungicide activity. The proteins and  
 CC nucleotide sequences are useful as nutritional sources or supplements  
 CC and in research. The proteins are useful for treating immune deficiency  
 CC and disorders, which may be genetic or resulting from infections,  
 CC autoimmune disorders such as multiple sclerosis, systemic lupus  
 CC erythematosus, rheumatoid arthritis, and for treating myeloid or lymphoid  
 CC cell deficiencies such as anaemias by regulating haematopoiesis. The  
 CC proteins are also useful in compositions for bone, cartilage, tendon,  
 CC ligament and/or nerve tissue growth or regeneration, for wound healing,  
 CC tissue repair and replacement and in the treatment of wounds, incisions  
 CC and ulcers. Other uses include in the treatment of central and  
 CC peripheral nervous system and neuropathies such as Alzheimer's and  
 CC Parkinson's diseases and Shy-Drager syndrome, and mechanical and  
 CC traumatic disorders, such as spinal cord disorders, head trauma and  
 CC stroke. The proteins may also be used as a contraceptive, and for  
 CC treating coagulation disorders such as haemophilias. The protein and  
 CC nucleotide sequences with cadherin activity are useful for treating  
 CC cancer. Other uses for the protein include for inhibiting the growth,  
 CC infection or function of, or killing, infectious agents such as bacteria,  
 CC virus, fungi and other parasites, for effecting bodily characteristics  
 CC such as height, weight, hair colour, effecting biorythms or cardiac  
 CC cycles or rhythms, effecting metabolism, catabolism, anabolism,  
 CC processing, utilization, storage or elimination of dietary fat, lipid,  
 CC protein, carbohydrate, vitamins, minerals, cofactors, effecting  
 CC behavioural characteristics, providing analgesic effects and for treating  
 CC hyperproliferative disorders such as psoriasis.  
 CC  
 XX  
 SQ Sequence 119 AA;  
 Query Match 100.0%; Score 644; DB 21; Length 119;  
 Best Local Similarity 100.0%; Pred. No. 1.7e-66;  
 Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDGOASRRWLDEGGQECCKDWFLRAP 60  
 DB 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDGOASRRWLDEGGQECCKDWFLRAP 60  
 QY 61 RRFEMTVSGLPKKQPCDHFGRGNVKTTRHORHRRPKKHSRACQFLKQCOLSFALPL 119  
 DB 61 RRFEMTVSGLPKKQPCDHFGRGNVKTTRHORHRRPKKHSRACQFLKQCOLSFALPL 119

RESULT 2  
 AAY82453  
 ID AAY82453 standard; Protein: 119 AA.  
 XX  
 AC AAY82453;  
 XX  
 DT 30-JUN-2000 (first entry)  
 XX  
 DE Human TGC-440 secretory protein SEQ ID NO:1.  
 XX

KW TGC-440; secretory protein; immunological disease; infectious disease;  
 KW pulmonary function disorder; hepatic function disorder; nephrotropic;  
 KW gastrointestinal function disorder; antiinflammatory; immunomodulatory;  
 KW virucide; hepatotropic; antitastmatic; antibacterial; vaccine;  
 KW hepatitis; nephritis; influenza; asthma; pulmonary hypertension;  
 KW pneumonia; Helicobacter pylori infection.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO200014226-A1.  
 XX  
 PN 16-MAR-2000.  
 PD  
 XX  
 XX 02-SEP-1999; 99WO-JP04765.  
 PE  
 XX 03-SEP-1998; 98JP-0250108.  
 PR  
 XX (TAKE ) TAKEDA CHEM IND LTD.  
 PA  
 XX Itoh Y, Og1 K, Tanaka H, Kitada C;  
 PI  
 XX  
 XX WPI; 2000-256978/22.  
 DR  
 DR N-PSDB; AAA08343, AAA08344.  
 XX  
 XX Secretory protein TGC440, antibodies to it and compounds promoting or  
 PT inhibiting its activity for diagnosis and treatment of diseases of the  
 PT immune system, lung, kidney, liver and intestinal system  
 PS  
 XX Claim 1; Fig 1; 86pp; Japanese.  
 XX  
 XX The present sequence represents a human secretory protein designated  
 CC TGC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory,  
 CC virucide, hepatotropic, antitastmatic and antibacterial activities,  
 CC and can be used in vaccines. TGC-440 and the polynucleotide sequence  
 CC encoding it can be used to treat, prevent and diagnose immunological,  
 CC lung, liver, kidney or gastrointestinal disorders and infectious  
 CC diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,  
 CC pulmonary hypertension, and Helicobacter pylori infection. An antibody  
 CC immunospecific for TGC-440 is also useful in the above treatment and  
 CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid  
 CC specimen.  
 CC  
 XX  
 SQ Sequence 119 AA;  
 Query Match 100.0%; Score 644; DB 21; Length 119;  
 Best Local Similarity 100.0%; Pred. No. 1.7e-66;  
 Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDGOASRRWLDEGGQECCKDWFLRAP 60  
 DB 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDGOASRRWLDEGGQECCKDWFLRAP 60  
 QY 61 RRFEMTVSGLPKKQPCDHFGRGNVKTTRHORHRRPKKHSRACQFLKQCOLSFALPL 119  
 DB 61 RRFEMTVSGLPKKQPCDHFGRGNVKTTRHORHRRPKKHSRACQFLKQCOLSFALPL 119

RESULT 3  
 AAY87317  
 ID AAY87317 standard; Protein: 119 AA.  
 XX  
 AC AAY87317;  
 XX  
 DT 11-MAY-2000 (first entry)  
 XX  
 DE Human signal peptide containing protein HSP-94 SEQ ID NO:94.  
 XX  
 XX Human; signal peptide-containing protein; HSP; diagnosis; cancer;  
 KW inflammation; cardiovascular disease; anticancer; anti-inflammatory;  
 KW antimicrobial; nootropic; neuroprotective; cardiovascular; hepatotropic;  
 KW antitastmatic; gene therapy; cell proliferation; neurological disorder;  
 KW reproductive disorder; developmental disorder; arteriosclerosis;  
 KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;  
 KW

KW asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;  
KW Parkinson's disease; Huntington's diseases; ovulatory defect;  
KW muscular dystrophy.  
OS Homo sapiens.  
XX  
XX WO200000610-A2.  
PN  
XX  
XX 06-JAN-2000.  
PD  
XX  
XX 25-JUN-1999; 99WO-US14484.  
PF  
XX  
XX 26-JUN-1998; 98US-0090762.  
PR  
XX 31-JUL-1998; 98US-0094983.  
PR  
XX 01-OCT-1998; 98US-0102686.  
PR  
XX 11-DEC-1998; 98US-0112129.  
XX  
XX (INCYTE PHARM INC.  
PA  
XX  
XX Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;  
PI Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;  
PI Bandman O;  
XX  
XX WPT. 2000-160673/14.  
DR  
XX N-PSDB; AA298202.  
XX  
XX  
XX New human signal peptide-containing proteins useful in treatment,  
PT prevention and diagnosis of e.g. cancer, inflammation and  
PT cardiovascular disease  
PS  
XX  
XX Claim 1; Page 220-221; 327pp; English.  
XX  
XX AA298109 to AA298242 encode AAY87224 to AAY87357 which represent the  
CC human signal peptide-containing proteins HSP-1 to HSP-134. HSPs have  
CC anticancer, anti-inflammatory, antimicrobial, nootropic, hepatotropic,  
CC neuroprotective, cardiovascular and antistatic activities, and can  
CC be used in gene therapy. HSPs can be used to treat or prevent disorders  
CC associated with decreased activity or function of HSP. Antagonists of  
CC HSP are used to treat or prevent disorders associated with increased  
CC activity or function of HSP. Such diseases include cell proliferation  
CC (including cancer), inflammation, cardiovascular, neurological,  
CC reproductive or developmental disorders, (e.g. arteriosclerosis,  
CC cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia,  
CC asthma, Crohn's disease, microbial or other infections, congestive or  
CC ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's  
CC diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSP  
CC nucleic acids can be used for the recombinant production of HSP, for  
CC detecting HSP in standard hybridisation and amplification assays (for  
CC diagnosis and monitoring), in gene therapy, as antisense,  
CC triplex-forming or ribozyme therapeutics, for detecting related sequences  
CC or genetic variations, and for chromosomal mapping. HSP are also used to  
CC raise specific antibodies (Ab) and to screen for agonists and  
CC antagonists (potential therapeutic agents). Ab are used to diagnose, or  
CC monitor, HSP-related diseases (in usual immunoassays), as therapeutic  
CC antagonists, in competitive drug screens, and for purification of HSP  
CC from natural sources.  
XX  
XX  
SQ Sequence 119 AA;  
Query Match 100.0%; Score 644; DB 21; Length 119;  
Best Local Similarity 100.0%; Pred. No. 1,76-66;  
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

AA66668  
ID AAY66668 standard; protein; 119 AA.  
XX  
XX  
AC AAY66668;  
XX  
XX  
DT 05-APR-2000 (first entry)  
XX  
XX  
DE Membrane-bound protein PRO842.  
XX  
XX  
KW Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;  
KW pharmacological; receptor immunoadhesin; gene mapping.  
XX  
XX  
OS Homo sapiens.  
XX  
XX  
PN WO963088-A2.  
XX  
XX 09-DEC-1999.  
PD  
XX  
XX  
PF 02-JUN-1999; 99WO-US12252.  
XX  
XX  
XX 02-JUN-1998; 98US-0087607.  
PR 02-JUN-1998; 98US-0087609.  
XX  
XX 02-JUN-1998; 98US-0087759.  
PR 03-JUN-1998; 98US-0087827.  
XX  
XX 04-JUN-1998; 98US-0088021.  
PR 04-JUN-1998; 98US-0088025.  
XX  
XX 04-JUN-1998; 98US-0088028.  
PR 04-JUN-1998; 98US-0088029.  
XX  
XX 04-JUN-1998; 98US-0088030.  
PR 04-JUN-1998; 98US-0088033.  
XX  
XX 04-JUN-1998; 98US-0088326.  
PR 05-JUN-1998; 98US-0088167.  
XX  
XX 05-JUN-1998; 98US-0088167.  
PR 05-JUN-1998; 98US-0088202.  
XX  
XX 05-JUN-1998; 98US-0088212.  
PR 05-JUN-1998; 98US-0088217.  
XX  
XX 09-JUN-1998; 98US-0088655.  
PR 10-JUN-1998; 98US-0088722.  
XX  
XX 10-JUN-1998; 98US-0088730.  
PR 10-JUN-1998; 98US-0088734.  
XX  
XX 10-JUN-1998; 98US-0088738.  
PR 10-JUN-1998; 98US-0088740.  
XX  
XX 10-JUN-1998; 98US-0088741.  
PR 10-JUN-1998; 98US-0088742.  
XX  
XX 10-JUN-1998; 98US-0088810.  
PR 10-JUN-1998; 98US-0088811.  
XX  
XX 10-JUN-1998; 98US-0088824.  
PR 10-JUN-1998; 98US-0088825.  
XX  
XX 10-JUN-1998; 98US-0088826.  
PR 11-JUN-1998; 98US-0088858.  
XX  
XX 11-JUN-1998; 98US-0088861.  
PR 11-JUN-1998; 98US-0088863.  
XX  
XX 11-JUN-1998; 98US-0088876.  
PR 12-JUN-1998; 98US-0088990.  
XX  
XX 12-JUN-1998; 98US-0089105.  
PR 16-JUN-1998; 98US-0089440.  
XX  
XX 16-JUN-1998; 98US-0089512.  
PR 16-JUN-1998; 98US-0089514.  
XX  
XX 17-JUN-1998; 98US-0089532.  
PR 17-JUN-1998; 98US-0089538.  
XX  
XX 17-JUN-1998; 98US-0089598.  
PR 17-JUN-1998; 98US-0089599.  
XX  
XX 17-JUN-1998; 98US-0089600.  
PR 17-JUN-1998; 98US-0089653.  
XX  
XX 18-JUN-1998; 98US-0089801.  
PR 18-JUN-1998; 98US-0089807.  
XX  
XX 18-JUN-1998; 98US-0089908.  
PR 19-JUN-1998; 98US-0089947.  
XX  
XX 19-JUN-1998; 98US-0089948.  
PR 19-JUN-1998; 98US-0089952.  
XX  
XX 22-JUN-1998; 98US-0090246.  
PR 22-JUN-1998; 98US-0090252.  
XX  
XX 22-JUN-1998; 98US-0090254.  
PR 23-JUN-1998; 98US-0090349.

```

PR 23-JUN-1998; 98US-0090355.
PR 24-JUN-1998; 98US-0090429.
PR 24-JUN-1998; 98US-0090431.
PR 24-JUN-1998; 98US-0090435.
PR 24-JUN-1998; 98US-0090444.
PR 24-JUN-1998; 98US-0090445.
PR 24-JUN-1998; 98US-0090461.
PR 24-JUN-1998; 98US-0090472.
PR 24-JUN-1998; 98US-0090535.
PR 24-JUN-1998; 98US-0090538.
PR 24-JUN-1998; 98US-0090540.
PR 24-JUN-1998; 98US-0090557.
PR 25-JUN-1998; 98US-0090676.
PR 25-JUN-1998; 98US-0090678.
PR 25-JUN-1998; 98US-0090688.
PR 25-JUN-1998; 98US-0090690.
PR 25-JUN-1998; 98US-0090691.
PR 25-JUN-1998; 98US-0090694.
PR 25-JUN-1998; 98US-0090695.
PR 25-JUN-1998; 98US-0090696.
PR 26-JUN-1998; 98US-0090862.
PR 26-JUN-1998; 98US-0090863.
PR 01-JUL-1998; 98US-0091358.
PR 01-JUL-1998; 98US-0091360.
PR 01-JUL-1998; 98US-0091544.
PR 02-JUL-1998; 98US-0091478.
PR 02-JUL-1998; 98US-0091486.
PR 02-JUL-1998; 98US-0091519.
PR 02-JUL-1998; 98US-0091626.
PR 02-JUL-1998; 98US-0091628.
PR 02-JUL-1998; 98US-0091633.
PR 02-JUL-1998; 98US-0091646.
PR 07-JUL-1998; 98US-0091973.
PR 07-JUL-1998; 98US-0091978.
PR 09-JUL-1998; 98US-0091982.
PR 10-JUL-1998; 98US-0092482.
PR 20-JUL-1998; 98US-0093339.
PR 30-JUL-1998; 98US-0094651.
PR 04-AUG-1998; 98US-0095282.
PR 04-AUG-1998; 98US-0095285.
PR 04-AUG-1998; 98US-0095301.
PR 04-AUG-1998; 98US-0095302.
PR 04-AUG-1998; 98US-0095316.
PR 04-AUG-1998; 98US-0095321.
PR 04-AUG-1998; 98US-0095325.
PR 10-AUG-1998; 98US-0095916.
PR 10-AUG-1998; 98US-0095929.
PR 10-AUG-1998; 98US-0096012.
PR 11-AUG-1998; 98US-0096143.
PR 11-AUG-1998; 98US-0096146.
PR 12-AUG-1998; 98US-0096329.
PR 17-AUG-1998; 98US-0096329.
PR 17-AUG-1998; 98US-0096757.
PR 17-AUG-1998; 98US-0096766.
PR 17-AUG-1998; 98US-0096768.
PR 17-AUG-1998; 98US-0096773.
PR 17-AUG-1998; 98US-0096791.
PR 17-AUG-1998; 98US-0096867.
PR 17-AUG-1998; 98US-0096891.
PR 17-AUG-1998; 98US-0096894.
PR 17-AUG-1998; 98US-0096895.
PR 17-AUG-1998; 98US-0096897.
PR 18-AUG-1998; 98US-0096949.
PR 18-AUG-1998; 98US-0096950.
PR 18-AUG-1998; 98US-0096959.
PR 18-AUG-1998; 98US-0096960.
PR 18-AUG-1998; 98US-0097022.
PR 19-AUG-1998; 98US-0097144.
PR 20-AUG-1998; 98US-0097218.
PR 24-AUG-1998; 98US-0097661.
PR 26-AUG-1998; 98US-0097951.
PR 26-AUG-1998; 98US-0097952.
PR 26-AUG-1998; 98US-0097954.

```

```

PR 26-AUG-1998; 98US-0097955.
PR 26-AUG-1998; 98US-0097971.
PR 26-AUG-1998; 98US-0097974.
PR 26-AUG-1998; 98US-0097978.
PR 26-AUG-1998; 98US-0097986.
PR 26-AUG-1998; 98US-0097986.
PR 26-AUG-1998; 98US-0098014.
PR 31-AUG-1998; 98US-0098525.
PR 16-SEP-1998; 98US-0100634.
PR 12-JAN-1999; 99US-0115565.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker K, Chen J, Goddard A, Gurney AL, Smith V, Matanabe CK;
PI Wood WI, Yvan J;
XX
XX WPI, 2000-072883/06.
DR N-PDB; AAZ65001.
XX
XX Membrane-bound proteins and related nucleotide sequences -
XX
XX claim 12; Fig 99; 822pp; English.
PS
XX
XX The invention provides membrane-bound PRO polypeptides and
CC polynucleotides encoding them. The PRO sequences of the invention were
CC identified based on extracellular domain homology screening. The PRO
CC sequences have homology with proteins including LDL receptors, TIE
CC ligands and various enzymes. The membrane-bound proteins and receptor
CC molecules are useful as pharmaceutical and diagnostic agents. Receptor
CC immunoadhesins, for instance, can be used as therapeutic agents to block
CC receptor-ligand interactions. The membrane-bound proteins can also be
CC employed for screening of potential peptide or small molecule inhibitors
CC of the relevant receptor/ligand interaction. The PRO encoding sequences
CC are useful as hybridization probes, in chromosome and gene mapping and in
CC the generation of antisense RNA and DNA. PRO nucleic acid sequences
CC will also be useful for the preparation of PRO polypeptides, especially
CC by recombinant techniques.
XX
XX Sequence 119 AA:
SQ
Query Match 100.0%; Score 644; DB 21; Length 119;
Best Local Similarity 100.0%; Pred. No. 1,7e-66;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MKVLISLLILLLPLIMLSWSSSLNPGVARGHRDGOASRRMLQSGGCECKDMFLRAP 60
DB 1 MKVLISLLILLLPLIMLSWSSSLNPGVARGHRDGOASRRMLQSGGCECKDMFLRAP 60
QY 61 RREKMTVSGLPKKQCPDHFKGNVKKTRHQRHRRKPNKHSRACQQLKQCOLRSPALPL 119
DB 61 RREKMTVSGLPKKQCPDHFKGNVKKTRHQRHRRKPNKHSRACQQLKQCOLRSPALPL 119
RESULT 5
AAU29093
ID AAU29093 standard; Protein; 119 AA.
XX
XX AAU29093;
AC
XX
XX 18-DEC-2001 (first entry)
DT
XX
XX Human PRO polypeptide sequence #70.
DE
XX
XX PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep;
KW dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;
KW blood; chondrocyte cell; cell proliferation; cell differentiation; colon;
KW adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder.
XX
XX Homo sapiens.
OS
XX
XX WO200168848-A2.
XX
XX 20-SEP-2001.
PD

```

XX 28-FEB-2001; 2001WO-US06520.  
 XX  
 PR 01-MAR-2000; 2000WO-US05601.  
 PR 02-MAR-2000; 2000WO-US05841.  
 PR 03-MAR-2000; 2000US-187202P.  
 PR 06-MAR-2000; 2000US-186368P.  
 PR 14-MAR-2000; 2000US-189320P.  
 PR 15-MAR-2000; 2000WO-US06884.  
 PR 21-MAR-2000; 2000US-190828P.  
 PR 21-MAR-2000; 2000US-191007P.  
 PR 21-MAR-2000; 2000US-191048P.  
 PR 21-MAR-2000; 2000US-191314P.  
 PR 28-MAR-2000; 2000US-192655P.  
 PR 29-MAR-2000; 2000US-193032P.  
 PR 29-MAR-2000; 2000US-193053P.  
 PR 30-MAR-2000; 2000WO-US08439.  
 PR 04-APR-2000; 2000US-194449P.  
 PR 04-APR-2000; 2000US-194647P.  
 PR 11-APR-2000; 2000US-195975P.  
 PR 11-APR-2000; 2000US-196000P.  
 PR 11-APR-2000; 2000US-196187P.  
 PR 11-APR-2000; 2000US-196690P.  
 PR 11-APR-2000; 2000US-196820P.  
 PR 18-APR-2000; 2000US-198121P.  
 PR 18-APR-2000; 2000US-198585P.  
 PR 25-APR-2000; 2000US-199397P.  
 PR 25-APR-2000; 2000US-199550P.  
 PR 25-APR-2000; 2000US-199654P.  
 PR 03-MAY-2000; 2000US-201516P.  
 PR 17-MAY-2000; 2000WO-US13705.  
 PR 22-MAY-2000; 2000WO-US14042.  
 PR 30-MAY-2000; 2000WO-US14941.  
 PR 02-JUN-2000; 2000WO-US15264.  
 PR 05-JUN-2000; 2000US-209632P.  
 PR 28-JUL-2000; 2000WO-US20710.  
 PR 22-AUG-2000; 2000US-0644848.  
 PR 24-AUG-2000; 2000WO-US23328.  
 PR 08-NOV-2000; 2000WO-US30952.  
 PR 01-DEC-2000; 2000WO-US32678.  
 PR 20-DEC-2000; 2000WO-US34956.  
 XX  
 PA (GENTECH ) GENENTECH INC.  
 XX  
 PI Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;  
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI; 2001-602746/68.  
 DR N-PSDB; AAS45394.  
 XX  
 PT Novel nucleic acids encoding PRO polypeptides, used to diagnose the  
 PT presence of tumours, such as prostate and breast tumours, in mammals and  
 PT to screen for modulators of the compounds -  
 PS  
 PS Claim 11; Fig 140; 774pp; English.  
 CC Sequences AAU9024-AAU92328 represent PRO polypeptides of the invention.  
 CC The PRO polypeptides and their associated nucleic acids can be used to  
 CC detect the presence of a tumour in a mammal by comparing the level of  
 CC expression of a PRO polypeptide in a test sample of cells from the animal  
 CC and a control sample of normal cells, whereby a higher level of  
 CC expression in the test sample indicates the presence of a tumour in the  
 CC mammal. Mammals include dogs, cats, cattle, horses, sheep, pigs, goats  
 CC and rabbits but are preferably human. The polypeptides can be used to  
 CC stimulate tumour necrosis factor (TNF) alpha release from human blood,  
 CC when contacted with it. A specific polypeptide can be used to stimulate  
 CC the proliferation or differentiation of chondrocyte cells. The PRO  
 CC proteins can be used to determine the presence of tumours and also  
 CC susceptibility to tumour development, particularly adrenal, lung, colon,  
 CC breast, prostate, rectal, cervical, or liver tumours, in mammalian  
 CC subjects. The oligonucleotide probes specific for the PRO nucleic acids  
 CC can be used for genetic analysis of individuals with genetic disorders.

XX SQ Sequence 119 AA;  
 Query Match 100.0%; Score 644; DB 22; Length 119;  
 Best Local Similarity 100.0%; Pred. No. 1.7e-66;  
 Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDGOASRRWLQEGGCECKDWFLRAP 60  
 DB 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDGOASRRWLQEGGCECKDWFLRAP 60  
 OY 61 RRRKFTVSGLPKKQCPDFKGVKTRRQRRHRRKRNKSRACQDFLKKCOLRSPFLPL 119  
 DB 61 RRRKFTVSGLPKKQCPDFKGVKTRRQRRHRRKRNKSRACQDFLKKCOLRSPFLPL 119  
 RESULT 6  
 AAG63977  
 ID AAG63977 standard; Protein; 119 AA.  
 XX  
 AC AAG63977;  
 XX  
 DT 13-NOV-2001 (first entry)  
 XX  
 DE Amino acid sequence of a human lng104 polypeptide.  
 XX  
 KW Human; lung cancer specific gene; LSG; lng104; lung cancer.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200161055-A2.  
 PD  
 PD 23-AUG-2001.  
 XX  
 PF 20-FEB-2001; 2001WO-US05674.  
 XX  
 PR 17-FEB-2000; 2000US-0183188.  
 XX  
 PA (DIAD-) DIADEXUS INC.  
 XX  
 PI Chen S, Sun Y, Macina RA;  
 XX  
 DR WPI; 2001-529917/58.  
 DR N-PSDB; AAH77949; AAH77951.  
 XX  
 PT New lung cancer specific gene for the treatment and diagnosis of lung  
 PT cancer -  
 PS  
 PS Claim 2; Page 115-116; 119pp; English.  
 CC  
 CC The present sequence is encoded by a human lung cancer specific gene  
 CC (LSG), and represents a polypeptide designated lng104. LSGs are useful  
 CC in the treatment and diagnosis of lung cancer. The treatment of lung  
 CC cancer comprises the administration of a molecule which down regulates  
 CC the expression of an LSG. An immune response can be mounted against a  
 CC target cell expressing an LSG. Identification of potential therapeutic  
 CC agents for use in imaging and treating lung cancer which comprises  
 CC screening molecules for an ability to bind to or decrease expression  
 CC of an LSG relative to LSG in the absence of the agent where the ability  
 CC of a molecule to bind to the LSG or decrease expression of the LSG is  
 CC indicative of the molecule being useful in imaging and treating lung  
 CC cancer.  
 XX  
 SQ Sequence 119 AA;  
 Query Match 100.0%; Score 644; DB 22; Length 119;  
 Best Local Similarity 100.0%; Pred. No. 1.7e-66;  
 Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDGOASRRWLQEGGCECKDWFLRAP 60  
 DB 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDGOASRRWLQEGGCECKDWFLRAP 60

OY 61 RREKMTVSGLPKQCCPDHFKGNVKKTRRQHRHRRKPNKHSRACQOFLKQCQLRSFALPL 119  
 Db 61 RREKMTVSGLPKQCCPDHFKGNVKKTRRQHRHRRKPNKHSRACQOFLKQCQLRSFALPL 119

RESULT 7  
 ID AAB87538 standard; Protein; 119 AA.  
 AC AAB87538;

DT 15-MAY-2001 (first entry)

DE Human PRO842.

KW Human; PRO protein; mapping.

OS Homo sapiens.

PN WO200116318-A2.

PD 08-MAR-2001.

PF 24-AUG-2000; 2000WO-US23328.

PR 01-SEP-1999; 99WO-US20111.

PR 15-SEP-1999; 99WO-US21090.

PR 07-DEC-1999; 99US-0169495.

PR 09-DEC-1999; 99US-0170262.

PR 11-JAN-2000; 2000US-0175481.

PR 18-FEB-2000; 2000WO-US04341.

PR 22-FEB-2000; 2000WO-US04414.

PR 01-MAR-2000; 2000WO-US05601.

PR 03-MAR-2000; 2000US-0187202.

PR 25-APR-2000; 2000US-0193997.

PR 22-MAY-2000; 2000WO-US14042.

PR 05-JUN-2000; 2000US-0209832.

XX (GETH ) GENENTECH INC.

PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi CJ, Gunney AL, Watanabe CK, Wood WI;

XX WPI: 2001-183260/18.

DR N-PSDB; AAF92070.

XX Eighty four nucleic acids encoding PRO polypeptides, useful in

PT molecular biology, including use as hybridization probes, and in

XX chromosome and gene mapping.

PS Claim 12; Fig 26; 278pp; English.

XX The present sequence is a human PRO polypeptide (secreted and

CC transmembrane). The PRO protein, and PRO agonists, PRO antagonists or

CC anti-PRO antibodies are useful for preparation of a medicament useful in

CC the treatment of a condition which is responsive to the PRO protein.

CC agonists, antagonists or anti-PRO antibodies. The PRO protein may also be

CC employed as molecular weight markers for protein electrophoresis. The PRO

CC coding sequence has applications in molecular biology, including use as

CC hybridisation probes, and in chromosome and gene mapping.

XX SQ Sequence 119 AA;

XX Query Match 100.0%; Score 644; DB 22; Length 119;

XX Best Local Similarity 100.0%; Pred. No. 1.7e-66;

XX Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MKVLISLILLLPLMLMSVSSSLNPGVARGHRDQASRRMLQEGGCECKDMFLRAP 60

Db 1 MKVLISLILLLPLMLMSVSSSLNPGVARGHRDQASRRMLQEGGCECKDMFLRAP 60

OY 61 RREKMTVSGLPKQCCPDHFKGNVKKTRRQHRHRRKPNKHSRACQOFLKQCQLRSFALPL 119

Db 61 RREKMTVSGLPKQCCPDHFKGNVKKTRRQHRHRRKPNKHSRACQOFLKQCQLRSFALPL 119

RESULT 8  
 ID AAB65191 standard; Protein; 119 AA.  
 AC AAB65191;

DT 02-APR-2001 (first entry)

DE Human PRO842 (UNQ473) protein sequence SEQ ID NO:165.

KW Human; secreted and transmembrane protein; PRO; cytosolic;

KW cell death; cancer; chromosomal mapping; gene mapping; tissue typing;

KW diagnostic assay.

OS Homo sapiens.

PN WO200073454-A1.

PD 07-DEC-2000.

PF 30-MAR-2000; 2000WO-US08439.

PR 02-JUN-1999; 99WO-US12252.

PR 23-JUN-1999; 99US-0141037.

PR 07-JUL-1999; 99US-0143048.

PR 20-JUL-1999; 99US-0144758.

PR 26-JUL-1999; 99US-0145698.

PR 28-JUL-1999; 99US-0146222.

PR 17-AUG-1999; 99US-0149396.

PR 15-SEP-1999; 99WO-US21090.

PR 15-SEP-1999; 99WO-US21547.

PR 08-OCT-1999; 99US-0158663.

PR 30-NOV-1999; 99WO-US28313.

PR 01-DEC-1999; 99WO-US28301.

PR 16-DEC-1999; 99WO-US30095.

PR 20-DEC-1999; 99WO-US30911.

PR 05-JAN-2000; 2000WO-US00219.

PR 06-JAN-2000; 2000WO-US00376.

PR 11-FEB-2000; 2000WO-US03565.

PR 18-FEB-2000; 2000WO-US04341.

PR 22-FEB-2000; 2000WO-US04914.

PR 24-FEB-2000; 2000WO-US05004.

PR 02-MAR-2000; 2000WO-US05841.

PR 15-MAR-2000; 2000WO-US06884.

PR 20-MAR-2000; 2000WO-US07377.

XX (GETH ) GENENTECH INC.

PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;

PI Ferrara N, Fong S, Geber H, Gerritsen ME, Goddard A, Godowski PJ;

PI Roy MA, Stewart TA, Tamas D, Watanabe CK, Williams PW, Wood WI;

XX Zhang Z;

XX WPI: 2001-032160/04.

DR N-PSDB; AAF4147.

XX PRO polynucleotides used to produce polypeptides used to target

PT bioactive molecules such as toxins, radiolabels or antibodies, to

PT specific cells, to cause targeted cell death.

XX Claim 12; Fig 99; 935pp; English.

XX The present invention describes human secreted and transmembrane PRO

CC proteins. The PRO proteins have cytostatic activity. The PRO proteins

CC can be used for targeted delivery of bioactive molecules, such as

CC toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide

CC sequences, and their fragments, can be used as hybridisation probes, in

CC chromosomal and gene mapping, and in the generation of anti-sense RNA  
CC and DNA. They may also be used to produce transgenic animals which are  
CC used to develop and screen therapeutically useful reagents. The PRO  
CC nucleotide and protein sequence can be used for tissue typing and in  
CC treating cancer. Anti-PRO antibodies can be used in diagnostic assays.  
CC AAF44270 to AAF44470 represent PCR primers and hybridisation probes used  
CC in the isolation of human PRO sequences. AAF44087 to AAF44269 and  
CC AAB65154 to AAB65300 represent human PRO polynucleotide and protein  
CC sequences given in the exemplification of the present invention.

XX Sequence 119 AA:

Query Match 100.0%; Score 644; DB 22; Length 119;  
Best Local Similarity 100.0%; Pred. No. 1.7e-66;  
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKVLSSLLPLMLMSVSSSLNPGVARGHDSRRRLDGGGCECKDWFLLAP 60  
DB 1 MKVLSSLLPLMLMSVSSSLNPGVARGHDSRRRLDGGGCECKDWFLLAP 60  
QY 61 RRRFMTVSGLPKQCPDHFKNVKTTRHQRHRRKPNKHSRACQDFLKOCOLRSFALPL 119  
DB 61 RRRFMTVSGLPKQCPDHFKNVKTTRHQRHRRKPNKHSRACQDFLKOCOLRSFALPL 119

RESULT 9

AAV82454  
ID AAV82454 standard; Protein; 97 AA.

XX AAV82454;  
DT 30-JUN-2000 (first entry)

DE Mature human TGC-440 secretory protein SEQ ID NO:7.

XX TGC-440; secretory protein; immunological disease; infectious disease;  
KW pulmonary function disorder; hepatic function disorder; nephrotropic;  
KW gastrointestinal function disorder; antiinflammatory;  
KW fibrinolytic; hepatotropic; antiasthmatic; antibacterial; vaccine;  
KW hepatitis; nephritis; influenza; asthma; pulmonary hypertension;  
KW pneumonia; Helicobacter pylori infection.

OS Homo sapiens.

XX MO200014226-A1.

PD 16-MAR-2000.

XX 02-SEP-1999; 99WO-JP04765.

XX 03-SEP-1998; 98JP-0250108.

XX (TAKE ) TAKEDA CHEM IND LTD.

XX Itoh Y, Ogi K, Tanaka H, Kitada C;

DR WPI: 2000-256978/22.

XX N-PSDB: AAA08345.

PT Secretory protein TGC440, antibodies to it and compounds promoting or  
PT inhibiting its activity for diagnosis and treatment of diseases of the  
PT immune system, lung, kidney, liver and intestinal system  
XX Disclosure: Page 80; 86pp; Japanese.

XX The present sequence represents the mature human secretory protein  
CC TGC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory,  
CC vituclide, hepatotropic, antiasthmatic and antibacterial activities,  
CC and can be used in vaccines. TGC-440 and the polynucleotide sequence  
CC encoding it can be used to treat, prevent and diagnose immunological,  
CC lung, liver, kidney or gastrointestinal disorders and infectious  
CC diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,  
CC pulmonary hypertension, and Helicobacter pylori infection. An antibody

CC Immunospecific for TGC-440 is also useful in the above treatment and  
CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid  
CC specimen.

XX Sequence 97 AA:

Query Match 85.1%; Score 548; DB 21; Length 97;  
Best Local Similarity 100.0%; Pred. No. 1.6e-55;  
Matches 97; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 23 SLNPGVARGHDSRRRLDGGGCECKDWFLLAPRRKFTVSGLPKQCPDHFKG 82  
DB 1 SLNPGVARGHDSRRRLDGGGCECKDWFLLAPRRKFTVSGLPKQCPDHFKG 60  
QY 83 NVKTRHQRHRRKPNKHSRACQDFLKOCOLRSFALPL 119  
DB 61 NVKTRHQRHRRKPNKHSRACQDFLKOCOLRSFALPL 97

RESULT 10

AAW83953  
ID AAW83953 standard; Protein; 93 AA.

XX AAW83953;

DT 28-JAN-1999 (first entry)

DE Polypeptide encoded by gene 7 clone HYPD64.

XX Secreted protein; gene therapy; protein therapy; diagnosis; treatment;  
KW central nervous system; CNS; immune system; cancer; trauma; liver;  
KW reproductive disorder; congenital malformation; degenerative disease;  
KW inflammatory disease; neoplasia; metabolic disorder; testis; placenta;  
KW brain; T cell; spleen; lung; heart; thymomyosarcoma; endocrine system;  
KW endocrinopathy; endocrine polyglandular syndrome; endocrine; sepsis;  
KW endocrine ophthalmopathy; osteoclastoma; bacterial infection; bone.

OS Homo sapiens.

XX WO9845712-A2.

XX 15-OCT-1998.

XX 07-APR-1998; 98WO-US06801.

XX 30-MAY-1997; 97US-0048184.

XX 08-APR-1997; 97US-0042726.

XX 08-APR-1997; 97US-0042727.

XX 08-APR-1997; 97US-0042728.

XX 08-APR-1997; 97US-0042754.

XX 08-APR-1997; 97US-0042825.

XX 30-MAY-1997; 97US-0048068.

XX 30-MAY-1997; 97US-0048070.

XX (HUMA-) HUMAN GENOME SCI INC.

XX Feng P, NI J, Rosen CA, Ruben SM, Yu G;

XX WPI: 1998-594496/50.

XX New isolated human genes and secreted polypeptide(s) they encode -  
XX useful for the diagnosis and treatment of e.g. cancers, CNS  
XX disorders, immune system disorders, inflammatory disease and  
XX bacterial infections

XX This represents a polypeptide encoded by the nucleic acid molecule  
CC designated Gene 7 from the human cDNA clone HYPD64 (deposited  
CC as clone ATCC 97955 and ATCC 209074) which encodes a human secreted  
CC protein of the invention. The gene is expressed primarily in liver,  
CC spleen, bone marrow and to a lesser extent in amygdala and is useful as  
CC reagents for differential identification of tissues in a biological

SEQIDNO: 53 (P126)







CC encoding it can be used to treat, prevent and diagnose immunological,  
CC lung, liver, kidney or gastrointestinal disorders and infectious  
CC diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,  
CC pulmonary hypertension, and Helicobacter pylori infection. An antibody  
CC immunospecific for TGC-440 is also useful in the above treatment and  
CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid  
CC specimen.

CC Sequence 97 AA:

Query Match 59.9%; Score 386; DB 21; Length 97;  
Best Local Similarity 71.1%; Pred. No. 8,3e-37;

Matches 69; Conservative 7; Mismatches 21; Indels 0; Gaps 0;

OY 23 SLNPGVANGHNRDQASRRMLQEGQCECKDMFLAPRRKMTVSGLPKQCPDHFNG 82  
1 SPNPGVAASHGQHLAPRRMLLEGQCECKDMFLQAPRRKMTAVLGPPRKQCPDHFNG 60  
DB 83 NVKTRHQRHRRKPKNHSRACQFLKQCOLRSFALPL 119  
61 REKKNRHQRHRRKSPRSRACQFLKQCHLASFALPL 97

RESULT 13  
AAV82455

ID AAV82455 standard; Protein; 119 AA.

AC AAV82455;

DT 30-JUN-2000 (first entry)

DE Rat TGC-440 secretory protein SEQ ID NO:2.

OS TGC-440: secretory protein; immunological disease; infectious disease;  
XX pulmonary function disorder; hepatic function disorder; nephrotropic;  
XX gastrintestinal function disorder; antinflammatory; immunomodulatory;  
XX virucide; hepatotropic; antisthmatic; antibacterial; vaccine;  
XX hepatitis; nephritis; influenza; asthma; pulmonary hypertension;  
XX pneumonia; Helicobacter pylori infection.

OS Ratus sp.

PN WO200014226-A1.

PD 16-MAR-2000.

PF 02-SEP-1999; 99WO-JP04765.

PR 03-SEP-1998; 98JP-0250108.

PA (TAKE ) TAKEDA CHEM IND LTD.

PI Itoh Y, Ogi K, Tanaka H, Kitada C;

DR WPI: 2000-256978/22.

DR N-PSDB; AAA08346; AAA08347.

PT Secretory protein TGC440, antibodies to it and compounds promoting or  
PT inhibiting its activity for diagnosis and treatment of diseases of the  
PT immune system, lung, kidney, liver and intestinal system  
XX  
XX Claim 1; Fig 2; 86pp; Japanese.

CC The present sequence represents a rat secretory protein designated  
CC TGC-440. TGC-440 has antinflammatory, nephrotropic, immunomodulatory,  
CC vitucide, hepatotropic, antisthmatic and antibacterial activities,  
CC and can be used in vaccines. TGC-440 and the polynucleotide sequence  
CC encoding it can be used to treat, prevent and diagnose immunological,  
CC lung, liver, kidney or gastrointestinal disorders and infectious  
CC diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,  
CC pulmonary hypertension, and Helicobacter pylori infection. An antibody  
CC immunospecific for TGC-440 is also useful in the above treatment and  
CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid

CC specimen.

XX Sequence 119 AA:

Query Match 59.9%; Score 386; DB 21; Length 119;  
Best Local Similarity 63.0%; Pred. No. 1.1e-36;  
Matches 75; Conservative 10; Mismatches 34; Indels 0; Gaps 0;

OY 1 MKVLISLLLLPLMIMSVSSSLNPGVARGHNRDQASRRMLQEGQCECKDMFLAP 60  
1 MKLMSFLLLLTGMFTATVSSSPNOEVARHHDQDQAPRRMLLEGQCECKDMFLAP 60  
DB 61 RRRKMTVSGLPKQCPDHFNGKVKTRHQRHRRKPKNHSRACQFLKQCOLRSFALPL 119  
61 KRRTRVLEPPRRKQCPDHFNGKVKTRHQRHRRKPKNHSRACQFLKQCOLRSFALPL 119

RESULT 14

AAV11732

ID AAV11732 standard; Protein; 69 AA.

AC AAV11732;

DT 18-JUN-1999 (first entry)

DE Human 5' EST secreted protein SEQ ID No: 332.

OS Human; secreted protein; EST; expressed sequence tag; diagnosis;  
XX forensic; gene therapy; chromosome mapping; signal peptide; prostate;  
XX upstream regulatory sequence; cytokine activity; cell proliferation;  
XX differentiation; haematopoiesis regulation; tissue growth regulation;  
XX reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;  
XX thrombolytic; anti-inflammatory; tumour inhibition.

OS Homo sapiens.

PN WO9906550-A2.

PD 11-FEB-1999.

PF 31-JUL-1998; 98WO-1B01232.

PR 01-AUG-1997; 97US-0905144.

PA (GEST ) GENSET.

PI Duclert A, Dumas Milne Edwards J, Lacroix B;

DR WPI: 1999-153780/13.

DR N-PSDB; AAX40454.

PT New isolated prostate-derived nucleic acids - used to develop  
PT products which may have cytokine, immune regulatory, haematopoiesis  
PT regulating, anti-inflammatory or tumour inhibition activity  
XX  
XX Claim 34; Page 512; 675pp; English.

CC AAX40438 to AAX40715 represent 5' expressed sequence tags (ESTs) for  
CC human secreted proteins expressed in prostate, and encode the proteins  
CC given in AAV11716 to AAV11993 respectively. The proteins given represent  
CC the signal peptide and an N-terminal fragment of a secreted protein. The  
CC nucleic acid sequences can be used for producing secreted human gene  
CC products. They can also be used to develop products for diagnosis and  
CC therapy. The proteins obtained may have cytokine activity, cell  
CC proliferation and differentiation activity, haematopoiesis regulating  
CC activity, tissue growth regulating activity, reproductive hormone  
CC regulating activity, chemotactic/chemokinetic activity, haemostatic and  
CC thrombolytic activity, receptor/ligand activity, anti-inflammatory  
CC activity, tumour inhibition activity or other activities. The products  
CC can be used in forensic, gene therapy and chromosome mapping procedures.  
CC The sequences can also be used for obtaining corresponding promoter  
CC sequences. The nucleic acids encoding the signal peptides can be used for  
CC directing extracellular secretion of a polypeptide or the insertion of a

CC polypeptide into a membrane, or importing a polypeptide into a cell.

XX Sequence 69 AA;

Query Match 55.6%; Score 358; DB 20; Length 69;  
Best Local Similarity 100.0%; Pred. No. 9.4e-34;  
Matches 63; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKVLISLLILPLMLMSVSSSLNPGVARGHRDRGQASRRWLQSGQCECKDFLRAP 60  
1 MKVLISLLILPLMLMSVSSSLNPGVARGHRDRGQASRRWLQSGQCECKDFLRAP 60

QY 61 RRRKFTVSG 69  
61 RRRKFTVSG 69

RESULT 15  
AAV82456  
ID AAV82456 standard; Protein; 97 AA.

AC AAV82456;  
XX 30-JUN-2000 (first entry)

DE Mature rat TGC-440 secretory protein SEQ ID NO:8.

XX TGC-440; secretory protein; immunological disease; infectious disease;  
XX pulmonary function disorder; hepatic function disorder; nephrotropic;  
XX gastrointestinal function disorder; antiinflammatory; immunomodulatory;  
XX virucide; hepatotropic; antiasthmatic; antibacterial; vaccine;  
XX hepatitis; nephritis; influenza; asthma; pulmonary hypertension;  
XX pneumonia; Helicobacter pylori infection.

OS Rattus sp.

XX WO200014226-A1.

XX 16-MAR-2000.

XX 02-SEP-1999; 99WO-JP04765.

XX 03-SEP-1998; 98JP-0250108.

XX (TAKE ) TAKEDA CHEM IND LTD.

XX Itoh Y, Ogi K, Tanaka H, Kitada C;

XX WPI; 2000-256978/22.

XX N-PSDB; AAA08348.

PT Secretory protein TGC440, antibodies to it and compounds promoting or  
PT inhibiting its activity for diagnosis and treatment of diseases of the  
PT immune system, lung, kidney, liver and intestinal system

PS Disclosure: Page 81; 86pp; Japanese.

XX The present sequence represents a mature rat secretory protein designated  
CC TGC-440. TGC-440 has antiinflammatory, nephrotropic, immunomodulatory,  
CC virucide, hepatotropic, antiasthmatic and antibacterial activities,  
CC and can be used in vaccines. TGC-440 and the polynucleotide sequence  
CC encoding it can be used to treat, prevent and diagnose immunological,  
CC lung, liver, kidney or gastrointestinal disorders and infectious  
CC diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,  
CC pulmonary hypertension, and Helicobacter pylori infection. An antibody  
CC immunospecific for TGC-440 is also useful in the above treatment and  
CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid  
CC specimen.

XX Sequence 97 AA;

Query Match 53.1%; Score 342; DB 21; Length 97;  
Best Local Similarity 64.9%; Pred. No. 9.9e-32;

Matches 63; Conservative 8; Mismatches 26; Indels 0; Gaps 0;

QY 23 SLNPGVARGHRDRGQASRRWLQSGQCECKDFLRAPRRKFTVSGILPKKQCECHFKG 82  
DB 1 SFNDEVARHHGGDQDAPRRWLMSGQCECDCKDMSLRVSKRTTAVLEPRKQCCDHYKG 60

QY 83 NVKKTTRQRRHRRKPKNHSRACQOFLKQCLRSFALPL 119  
DB 61 SEKKNRQKHRRKSQRPSTCQOFLKRCQLASFALPL 97

Search completed: April 16, 2003, 12:15:12  
Job time : 38 secs